<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="36910"><DrugName>Org-37663</DrugName><DrugSynonyms><Name><Value>Org-37663</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="13880">MSD OSS BV</CompanyOriginator><CompaniesSecondary><Company id="13880">MSD OSS BV</Company></CompaniesSecondary><CrossReferences><SourceEntity id="36910" type="Drug"><TargetEntity id="329518" type="siDrug">Org-37663</TargetEntity></SourceEntity><SourceEntity id="13880" type="Company"><TargetEntity id="4298331728" type="organizationId">Organon Biosciences BV</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsSecondary><Action id="3189">Corticosteroid agonist</Action><Action id="2954">Steroidal anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology></Technologies><LastModificationDate>2017-08-23T06:06:02.000Z</LastModificationDate><ChangeDateLast>2007-07-24T13:55:32.000Z</ChangeDateLast><AddedDate>2001-11-19T11:46:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="13880" linkType="Company"&gt;Organon&lt;/ulink&gt; was developing Org-37663, a steroid, for the the potential treatment of rheumatoid arthritis (RA) [&lt;ulink linkID="429149" linkType="reference"&gt;429149&lt;/ulink&gt;], [&lt;ulink linkID="429698" linkType="reference"&gt;429698&lt;/ulink&gt;]. Phase II trials had begun in the US and Europe by January 2003 [&lt;ulink linkID="485548" linkType="reference"&gt;485548&lt;/ulink&gt;]; however, the program had been cancelled by November 2004 [&lt;ulink linkID="814983" linkType="Reference"&gt;814983&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;The compound had entered phase I trials in the US, Europe and Japan by October 2002 [&lt;ulink linkID="466916" linkType="reference"&gt;466916&lt;/ulink&gt;], [&lt;ulink linkID="470082" linkType="reference"&gt;470082&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="13880">MSD OSS BV</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-15T00:00:00.000Z</StatusDate><Source id="814983" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13880">MSD OSS BV</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-15T00:00:00.000Z</StatusDate><Source id="814983" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13880">MSD OSS BV</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-11-15T00:00:00.000Z</StatusDate><Source id="814983" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="13880">MSD OSS BV</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-10-14T00:00:00.000Z</StatusDate><Source id="466916" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13880">MSD OSS BV</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-10-14T00:00:00.000Z</StatusDate><Source id="466916" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13880">MSD OSS BV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-11-19T11:46:04.000Z</StatusDate><Source id="429149" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13880">MSD OSS BV</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-10-14T00:00:00.000Z</StatusDate><Source id="466916" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13880">MSD OSS BV</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-01-31T00:00:00.000Z</StatusDate><Source id="485548" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13880">MSD OSS BV</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-01-31T00:00:00.000Z</StatusDate><Source id="485548" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=814983" linkType="reference" linkID="814983"&gt;814983&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>